Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis

Arthritis & Rheumatism

Volumn 38, Issue 2, 1995, Pages 151-160

  Arend, William P ^a   Dayer, Jean‐Michel ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; LYMPHOTOXIN; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN ANTIBODY REACTION; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; JOINT DESTRUCTION; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEOGLYCAN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL; SYNOVITIS; T LYMPHOCYTE;

ANIMAL; ARTHRITIS, RHEUMATOID; HUMAN; INTERLEUKIN-1; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

EID: 0028861236     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780380202     Document Type: Article

References (101)

1. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
2. New directions for biological therapy in rheumatoid arthritis
3. Direct contact between T lymphocytes and monocytes is a major pathway for the induction of metalloproteinase expression
4. Criteria for identifying mediators of tissue damage in human autoimmune diseases
5. Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro
6. Inhibitory effect of TNF α antibodies on synovial cell interleukin‐1 production in rheumatoid arthritis
7. Arthritis induced by interleukin‐1 is dependent on the site and frequency of intraarticular injection
8. Induction of an acute erosive monarticular arthritis in mice by interleukin‐1 and methylated bovine serum albumin
9. Flare‐up of experimental arthritis in mice with murine recombinant IL‐1
10. Interleukin‐1 enhances the development of spontaneous arthritis in MRL/lpr mice
11. Interleukin‐1 enhances the development of type II collagen‐induced arthritis only in susceptible and not in resistant mice
12. Effects of murine recombinant interleukin‐1 on synovial joints in mice: measurement of patellar cartilage metabolism and joint inflammation
13. In vivo effects of interleukin‐1 on articular cartilage: prolongation of proteoglycan metabolic disturbances in old mice
14. Elevated substance P and accelerated cartilage degradation in rabbit knees injected with interleukin‐1 and tumor necrosis factor
15. Recombinant human interleukin‐1 β‐induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid
16. The role of stromelysin in the cartilage destruction that accompanies inflammatory arthritis
17. In vivo expression of stromelysin in synovium and cartilage of rabbits injected intraarticularly with interleukin‐1β
18. Transin/stromelysin expression in rheumatoid synovium
19. Localization of collagenase mRNA in rheumatoid arthritis synovium by in situ hybridization histochemistry
20. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium
21. Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin‐1 antibodies in experimental arthritis
22. Amelioration of established murine collagen‐induced arthritis with anti‐IL‐1 treatment
23. Antibody to interleukin‐1 inhibits the cartilage degradative and thymocyte proliferative actions of rheumatoid synovial culture medium
24. Interleukin‐1 receptor antagonist
25. Biological properties of recombinant human monocyte‐derived interleukin‐1 receptor antagonist
26. An interleukin‐1 inhibitor affects both cell‐associated interleukin‐1‐induced T cell proliferation and PGE2/collagenase production by human dermal fibroblasts and synovial cells
27. Natural and recombinant human IL‐1 receptor antagonists block the effects of IL‐1 on bone resorption and prostaglandin production
28. Modulation of the effects of interleukin‐1 on glycosaminoglycan synthesis by the urine‐derived interleukin‐1 inhibitor, but not by interleukin‐6
29. Biologic effects of an interleukin‐1 receptor antagonist protein on interleukin‐1‐stimulated cartilage erosion and chondrocyte responsiveness
30. Induction of neutral proteinase and prostanoid production in bovine nasal chondrocytes by interleukin‐1 and tumor necrosis factor α: modulation of these cellular responses by interleukin‐6 and platelet‐derived growth factor
31. Pro‐ and anti‐inflammatory roles of interleukin‐1 in recurrence of bacterial cell wall‐induced arthritis in rats
32. Production of IL‐1 and IL‐1 receptor antagonist and the pathological significance in lipopolysaccharide‐induced arthritis in rabbits
33. The effect of an interleukin‐1 receptor antagonist protein on type II collagen‐induced arthritis and antigen‐induced arthritis in mice
34. Inhibition of interleukin‐1‐induced synovitis and articular cartilage proteoglycan loss in the rabbit knee by recombinant human interleukin‐1 receptor antagonist
35. The effect of recombinant human interleukin‐1 receptor antagonist on the induction phase of antigen induced arthritis in the rabbit
36. Suppression of monocyte function and differential regulation of IL‐1 and IL‐lra by IL‐4 contribute to resolution of experimental arthritis
37. Cells with dendritic morphology and bright interleukin‐1 α staining circulate in the blood of patients with rheumatoid arthritis
38. Spontaneous release of angiotensin converting enzyme and interleukin‐1β from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition
39. Direct stimulation of cytokines (IL‐1β, TNF‐α, IL‐6, IFN γ and GM‐CSF) in whole blood. II. Application to rheumatoid arthritis and osteoarthritis
40. Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls
41. IL‐1 secreting cell assay and its application to cells from patients with rheumatoid arthritis
42. Cytokine inter‐relationships and their association with disease activity in arthritis
43. Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue
44. Levels of synovial fluid interleukin‐1 receptor antagonist in rheumatoid arthritis and other arthropathies: potential contribution from synovial fluid neutrophils
45. Balance of synovial fluid IL‐1β and IL‐1 receptor antagonist and recovery from Lyme disease
46. Quantitative analysis of cytokine gene expression in rheumatoid arthritis
47. Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair
48. In situ hybridization of interleukin‐1 in CD14‐positive cells in rheumatoid arthritis
49. Contrasting levels of in vitro cytokine production by rheumatoid synovial tissues demonstrating different patterns of mononuclear cell infiltration
50. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis
51. IL‐1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium
52. Expression of interleukin‐1 and interleukin‐1 receptor antagonist by human rheumatoid synovial tissue macrophages
53. Localization of interleukin‐1 α, type 1 interleukin‐1 receptor and interleukin‐1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis
54. Synovial interleukin‐1 receptor antagonist and interleukin‐1 balance in rheumatoid arthritis
55. The effect of gold sodium thiomalate and auranofin on lipopolysaccharide‐induced interleukin‐1 production by blood monocytes in vitro: variation in healthy subjects and patients with arthritis
56. The effects of methotrexate on interleukin‐1 in patients with rheumatoid arthritis
57. Methotrexate inhibits proliferation but not interleukin‐1‐stimulated secretory activities of cultured human synovial fibroblasts
58. Reduction of leukocyte and interleukin‐1 β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate
59. Inactivation of interleukin‐1β converting enzyme by peptide (acyloxy)methyl ketones
60. A soluble binding protein specific for interleukin‐1β is produced by activated mononuclear cells
61. Purification and characterization of a novel soluble receptor for interleukin‐1
62. Phase I study of recombinant human interleukin‐1 receptor administered intra‐articularly in active rheumatoid arthritis (abstract)
63. Subcutaneous IL‐1 receptor antagonist in patients with rheumatoid arthritis (abstract)
64. A dose‐and regimen‐ranging study of IL‐1 receptor antagonist in patients with rheumatoid arthritis (abstract)
65. Prospects for treating arthritis by gene therapy
66. Adenoviral‐mediated gene transfer to rabbit synovium in vivo
67. Genetic modification of synoviocytes in vivo using recombinant adenoviral vectors (abstract)
68. Intraarticular expression of biologically active interleukin‐1‐receptor‐antagonist protein by ex vivo gene transfer
69. TNFα‐a pivotal role in rheumatoid arthritis
70. The role of cytokines and their inhibitors in arthritis
71. Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor‐α
72. Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes
73. Involvement of platelet‐activating factor and tumor necrosis factor in the pathogenesis of joint inflammation in rabbits
74. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis
75. Effects of tumor necrosis alpha (TNF‐α) on collagen arthritis
76. Acceleration of onset of collagen‐induced arthritis by intraarticular injection of tumour necrosis factor or transforming growth factor‐beta
77. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice
78. Evolution of collagen arthritis in mice is arrested by treatment with anti‐tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
79. Anti‐tumor necrosis factor ameliorates joint disease in murine collagen‐induced arthritis
80. Synergy between anti‐CD4 and anti‐tumor necrosis factor in the amelioration of established collagen‐induced arthritis
81. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen‐induced arthritis in mice
82. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis
83. Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis
84. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage‐pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α
85. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints
86. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
87. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees
88. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor‐α production and protect mice against endotoxin challenge
89. Circulating soluble tumor necrosis factor receptors, interleukin‐2 receptors, tumor necrosis factor α, and interleukin‐6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy
90. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
91. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis
92. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids
93. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors
94. Soluble tumor necrosis factor receptor: results of a phase I dose‐escalation study in patients with rheumatoid arthritis (abstract)
95. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
96. TNF α blockade in rheumatoid arthritis: results of a multicenter placebo‐controlled, double‐blind trial of chimeric anti‐TNF α monoclonal antibody (cA2) in refractory disease (abstract)
97. A double blind, placebocontrolled, ascending dose trial of the recombinant humanised anti‐TNFα antibody CDP571 in patients with rheumatoid arthritis: a preliminary report (abstract)
98. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti‐TNF antibodies in patients with rheumatoid arthritis
99. The prospect for cytokine based therapeutic strategies in rheumatoid arthritis
100. Cytokine profile dependent on the type of arthritis: dominant role of IL‐1 in cartilage destruction (abtract)
101. Inhibition of tumor necrosis factor is effective alone or in combination with inhibition of interleukin‐1 in reducing joint swelling in rodent bacterial cell wall‐induced arthritis (abstract)